1.41
0.03 (2.03%)
| Penutupan Terdahulu | 1.38 |
| Jumlah Dagangan | 11,032 |
| Harga / Jualan (P/S) | 1.12 |
| Harga / Buku (P/B) | 9.89 |
| Julat 52 Minggu |
| Margin Keuntungan | -106.77% |
| Margin Operasi (TTM) | -52.24% |
| EPS Cair (TTM) | -2.64 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 49.70% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -60.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 778.95% |
| Nisbah Semasa (MRQ) | 0.380 |
| Aliran Tunai Operasi (OCF TTM) | -6.40 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 10.32 M |
| Pulangan Atas Aset (ROA TTM) | -17.42% |
| Pulangan Atas Ekuiti (ROE TTM) | -232.51% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Celularity Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 5.0 |
| Purata | -0.13 |
|
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 51.26% |
| % Dimiliki oleh Institusi | 14.66% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| C V Starr & Co Inc | 30 Jun 2026 | 764,069 |
| Biltmore Family Office, Llc | 30 Jun 2026 | 35,000 |
| Keynote Financial Services Llc | 30 Jun 2026 | 29,920 |
| Centerstar Asset Management, Llc | 30 Jun 2026 | 21,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |